These results suggest that the mechanisms underlying the cardioprotective effect of TRIM32 on the pathological cardiac hypertrophy could plausibly be dependent on inhibiting the prolonged activation of the Akt-dependent signalling pathways. This evidence concerns the gene AKT1 and cardiac hypertrophy.